Correlation between serum MMP-9 protein level and vascular cognitive impairment with no dementia in patients with cerebral small vessel diseases
10.3760/cma.j.cn371468-20200512-01355
- VernacularTitle:脑小血管病患者血清MMP-9水平与非痴呆性血管性认知功能障碍的相关性研究
- Author:
Jianhua ZHAO
1
;
Xue PENG
;
Lifang MENG
;
Hao LIU
;
Jin WANG
;
Shaomin LI
;
Junli LIU
;
Xianglei JIA
;
Panpan ZHAO
;
Fan WANG
;
Chaowei WANG
;
Lijun ZHANG
;
Qing LI
;
Jing REN
;
Sibei JI
;
Bin YUAN
Author Information
1. 新乡医学院第一附属医院神经内科 河南省神经修复重点实验室 河南省老年性痴呆神经修复国际联合实验室，新乡 453000
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2020;29(9):808-812
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between serum matrix metalloproteinase-9(MMP-9) level and vascular cognitive impairment with no dementia (VCIND) in patients with cerebral small vessel diseases (CSVD).Methods:A total of 374 patients with CSVD treated in the First Affiliated Hospital of Xinxiang Medical University from January 2016 to January 2020 were collected and 150 healthy subjects in the same period were used as general data of the control group. All subjects were detected for serum MMP-9 level using enzyme linked immunosorbent assay and received cognitive function scoring using Montreal cognitive assessment (MoCA). The 374 patients with CSVD were divided into the Group A(186 cases with vascular cognitive impairment with no dementia) and the Group B(188 cases without cognitive impairment). The general data, serum MMP-9 level and cognitive function score were compared among the three groups and the correlation between MMP-9 level and cognitive function was analyzed.Results:The MMP-9 levels of Groups A and B ( (335.10±105.10)μg/L, (261.62±80.32)μg/L) were higher than those of the control group ( (168.23±48.85)μg/L), and the MMP-9 level of Group A was higher than that of Group B ( P<0.05). The MoCA scores of Groups A and B ( (18.45±5.24), (28.31±1.52) ) were lower than those of the control group (29.49±0.90), and the MoCA scores of Group A were lower than those of Group B ( P<0.05). The serum MMP-9 level, a risk factor for VCIND in patients with CSVD ( β=1.505, OR=1.323, 95% CI=1.149-1.527, P<0.05), was negatively correlated with total score of MoCA scale, visual-spatial and executive function, naming, language, abstract thinking, delayed recall, and directive force factor score ( r=-0.299, r=-0.155, r=-0.383, r=-0.358, r=-0.192, r=-0.259, r=-0.246 respectively, all P<0.05). Conclusion:The increased level of MMP-9 may be a risk factor of VCIND in CSVD patients, and it is closely related to cognitive impairment.
